Will CalciMedica stock go up?

According to Danelfin AI, CalciMedica has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.10%) is -2.73% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for CalciMedica stock?

The CalciMedica target price is $0.97 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold CalciMedica stock right now?

CalciMedica has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (48.10%) is -2.73% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether CalciMedica stock is a good buy .

Is CalciMedica undervalued right now?

Based on analysts, the average price target downside for CalciMedica is 0.00% (1Y). According to Danelfin AI, CalciMedica has today an AI Score of 4/10 (Hold Rating).

What was the price range of CalciMedica stock over the past 12 months?

The CalciMedica stock price range over the past 12 months has been $0.51 - $6.74.

What is going on with CalciMedica stock in the last 3 months?

The CalciMedica stock performance in the last quarter has been +64.29%.

Does CalciMedica offer dividend payments?

No, CalciMedica does not currently pay dividends.

What is the current market capitalization of CalciMedica?

CalciMedica's market cap is $15.25M, as of 2026-07-03 08:00.

CalciMedica Inc (CALC) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

CALC AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, CalciMedica Inc today receives an AI Score of 4/10, which translates to a Hold rating. The stock has a 53% probability of outperforming the market in the next 3 months, which is 2% higher than the average probability of any stock (51%). Among the top positive contributors, the Technicals Impact (Long Tail) boosts the probability by +7.06%, the Chart Pattern (180d) adds +4.49%, and the Alpha Last Day contributes +3.93% despite being in the bottom 10%. Conversely, the main detractors include Institutional Ownership (bottom 20%) reducing probability by -5.17%, the Fear & Greed Index at 31 (extreme fear) detracting -4.72%, and Maximum Volatility (top 10%) weighing down by -4.26%. Notable data points include Beginning Cash of $11.52 million (bottom 20%) and Total Common Equity of -$1.10 million (bottom 10%), both signaling weak financial fundamentals. However, the Alpha Last Day of -0.07 (bottom 10%) and Performance YTD of -85.3% (bottom 10%) are paradoxically positive contributors, suggesting potential mean reversion. The Earnings Countdown of -45 days (bottom 30%) also adds a slight boost. Overall, the stock’s moderate probability of outperformance is supported by technical and momentum signals but constrained by poor fundamentals and high volatility, justifying the Hold rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+20.28%
Direction and strength of recent price movements
Growth+1.62%
Expected pace of revenue and earnings expansion

Valuation-7.71%
How the stock is priced relative to its fundamentals
Sentiment-6.55%
How analysts and the market view the stock
Size & Liquidity-4.03%
Company size and trading liquidity
Volatility-3.77%
How much the stock price tends to fluctuate
Financial Strength-2.56%
Balance sheet strength and financial resilience

CALC probability advantage of beating the market (3M):

-2.73%

Technical

CalciMedica (CALC) has a Technical Score of 6/10 because, according to only technical analysis, it has a probability advantage of +0.44% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.73%) and the probability of CALC (51.17%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.73%
CALC probability advantage of beating the market (only technical, 3M)+0.44%
CALC probability of beating the market (3M)51.17%

CALC probability advantage of beating the market (only technical, 3M): +0.44%

The AI-powered technical analysis of CalciMedica (CALC) is only based on the 28 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of CALC:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	+0.40%
Technical	Upgrade to Pro to unlock	-0.33%
Technical	Upgrade to Pro to unlock	+0.22%
Technical	Upgrade to Pro to unlock	-0.20%
Technical	Upgrade to Pro to unlock	+0.18%
Technical	Upgrade to Pro to unlock	+0.13%
Technical	Upgrade to Pro to unlock	-0.11%
Technical	Upgrade to Pro to unlock	-0.10%
Technical	Upgrade to Pro to unlock	+0.10%
Technical	Upgrade to Pro to unlock	-0.10%
Technical	Upgrade to Pro to unlock	+0.09%
Technical	Upgrade to Pro to unlock	-0.09%
Technical	Upgrade to Pro to unlock	+0.08%
Technical	Upgrade to Pro to unlock	+0.06%
Technical	Upgrade to Pro to unlock	-0.05%

Rest of Alpha Signals: -0.02%

CALC probability advantage of beating the market (only technical, 3M)Total:+0.44%
CALC Technical Score

Significant changes Vs previous day

CALC Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$0.97
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

CALC Proven Hold Signal & Price Forecast

This is the price chart for CALC from January 2, 2026 until today. The chart indicates, in yellow, the 56 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

CALC Average Past Performance & Win Rate

Three months after its 566 Hold signals since July 2026, CALC had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

566 Past CALC Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-38.53%
Average Alpha				-52.15%
Win Rate (% Positive Perf.)				19.13%
% Positive Alpha				17.49%

CALC Frequently Asked Questions

Will CalciMedica stock go up?
According to Danelfin AI, CalciMedica has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.10%) is -2.73% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for CalciMedica stock?
Is it a good time to buy, sell, or hold CalciMedica stock right now?
Is CalciMedica undervalued right now?
What was the price range of CalciMedica stock over the past 12 months?
What is going on with CalciMedica stock in the last 3 months?
Does CalciMedica offer dividend payments?
What is the current market capitalization of CalciMedica?

CalciMedica Inc Company Profile

CalciMedica, Inc. operates as a biotechnology entity in the clinical stage, working diligently to formulate novel therapies for inflammatory diseases deemed life-threatening and currently underserved. The company's proprietary technology holds its focus on the inhibition of calcium release-activated (CRAC) channels, a scientific approach crafted to adjust the immune response and safeguard cellular tissue from damage caused by severe inflammatory complications.

Auxora, CalciMedica's flagship product candidate, embodies this approach. It's an intravenous formulation of CRAC channel inhibitor meticulously developed for tackling acute pancreatitis and asparaginase-associated acute pancreatitis. In addition, it has shown promise in managing acute kidney injury scenarios.

The firm sets up shop in La Jolla, California, where it demonstrates relentless engagement with cutting-edge biotechnological advancements to improve patient outcomes in challenging health areas. Its commitment is unwavering as it continues breaking new grounds in addressing dire needs in today’s healthcare landscape.

Sector:
Country:United States
Industry:
Address:505 Coast Boulevard South, Suite 307, La Jolla
Employees:16
Website:calcimedica.com

Pros

Novel mechanism of action targeting Orai1 calcium channels

Addressing unmet medical need in acute pancreatitis

Broad applicability of Orai1 inhibition across inflammatory diseases

Proprietary intellectual property protecting lead compound

Potential for expedited regulatory pathways in rare indications

Cons

Inherent high risk of clinical trial failures

Substantial capital requirements for drug development

Lengthy and complex regulatory approval processes

Challenges in market access and reimbursement for new therapies

Concentrated pipeline risk on a single lead asset

Company	AI Score	Compare
DMACDiaMedica Therapeutics Inc
CVKDCadrenal Therapeutics Inc
ANIXAnixa Biosciences Inc
BDRXBiodexa Pharmaceuticals PLC
PCRXPacira Biosciences Inc

Company	AI Score	Compare
DMACDiaMedica Therapeutics Inc
CVKDCadrenal Therapeutics Inc
ANIXAnixa Biosciences Inc
BDRXBiodexa Pharmaceuticals PLC
PCRXPacira Biosciences Inc

CALC Stock AI Analysis High Risk

CalciMedica Inc

CALC Stock AI Analysis

CalciMedica Inc

CALC AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

CALC probability advantage of beating the market (only technical, 3M): +0.44%

CALC Trading Parameters

CALC Proven Hold Signal & Price Forecast

CALC Average Past Performance & Win Rate

CALC Frequently Asked Questions

Will CalciMedica stock go up?

What is the target price for CalciMedica stock?

Is it a good time to buy, sell, or hold CalciMedica stock right now?

Is CalciMedica undervalued right now?

What was the price range of CalciMedica stock over the past 12 months?

What is going on with CalciMedica stock in the last 3 months?

Does CalciMedica offer dividend payments?

What is the current market capitalization of CalciMedica?

CalciMedica Inc Company Profile

Pros

Cons

Pros

Cons

CALC Company Profile Summary

CALC Related Investment Themes

CALC Related Stocks

CALC Top 10 Industry Stocks

Pharmaceuticals

CALC Top 10 Sector Stocks

Health Care

CALC Stock AI Analysis High Risk

CalciMedica Inc

NASDAQ NMS - GLOBAL MARKET

Will CalciMedica stock go up?

What is the target price for CalciMedica stock?

Is it a good time to buy, sell, or hold CalciMedica stock right now?

Is CalciMedica undervalued right now?

What was the price range of CalciMedica stock over the past 12 months?

What is going on with CalciMedica stock in the last 3 months?

Does CalciMedica offer dividend payments?

What is the current market capitalization of CalciMedica?

CALC Proven Hold Signal & Price Forecast

NASDAQ NMS - GLOBAL MARKET

Pros

Cons

AI Score Explanation